Belgian biotech firm ThromboGenics, which is focussed on developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today announced it has strengthened its senior leadership team, attracting former executives from Allergan and Novartis. 8 November 2017
Chirfi Guindo has been appointed executive vice president and head of global marketing, market access and customer innovation at US biotech major Biogen. 3 November 2017
Swiss drugmaker Basilea Pharmaceutica has reported that Achim Kaufhold will retire from his post as chief medical officer after seven years with the company. 1 November 2017
Israel’s Teva Pharmaceutical Industries today announced that Kåre Schultz will join the company as president and chief executive, effective November 1, 2017. 31 October 2017
Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy treatments that are changing cancer care, has announced several key leadership appointments to further the company’s continued growth and expansion. 27 October 2017
Belgian biotech firm Ablynx saw its shares gain 2.3% to 18.28 euros as markets opened this morning and following the announcement that it is establishing a subsidiary in the USA. 16 October 2017
US pharma major Bristol-Myers Squibb (NYSE: BMY) has appointed scientific and business thought-leader, Saurabh Saha, senior vice president and global head of translational medicine in the company’s R&D organization, effective today. 9 October 2017
Norbert Oppitz has been appointed senior vice president for the newly-established business area Specialty Care at Nordic drugmaker Swedish Orphan Biovitrum, and will be part of Sobi’s executive leadership team. 6 October 2017
Privately-held Swiss drugmaker Ferring Pharmaceuticals has appointed Professor Klaus Dugi as executive vice president and chief medical officer (CMO), effective immediately. 3 October 2017
French pharma major Sanofi today announced the appointment of Stefan Oelrich as executive vice president Diabetes & Cardiovascular (DCV), effectively immediately. 2 October 2017
The fast-changing and pressurized environment in which they operate means pharma companies must now take a more aggressive approach to adopting new leadership structures, writes Waseem Noor, a consultant at the executive search firm Russell Reynolds Associates, in an Expert View piece. 28 September 2017
Massachusetts-based Rubius Therapeutics has shaken up its executive team, with new appointments in the firm’s medical, financial, legal and HR divisions. 28 September 2017
The share price of Ireland-incorporated drugmaker Allergan closed at $211.61 on Monday, up 3.4% for the day, after the company announced a $2 billion share buyback program and reiterated its pledge to pay down $3.75 billion of debt in 2018. 26 September 2017
Germany’s Merck KGaA (MRK: DE) has appointed Paolo Carli as head of Middle East, Africa & Turkey (MEA) region for its healthcare business. He will be responsible for leading the commercial operations for Merck across the MEA. 26 September 2017
A former researcher at Amgen has been named as the new chief scientific officer of UK-based cellular immunotherapy company Cell Medica. 18 September 2017
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024